Open AccessIntravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model
Author(s) -
Austin N. Kirschner,
Jian Wang,
Anne Rajkumar-Calkins,
Kevin Neuzil,
Sam S. Chang
Publication year - 2021
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1097/ju.0000000000001576
Subject(s) - medicine , bladder cancer , chemotherapy , urology , immunotherapy , transitional cell carcinoma , immune system , toxicity , urinary bladder , mitomycin c , antibody , immune checkpoint , cancer , cancer research , oncology , immunology , surgery
Nonmuscle-invasive bladder cancer is treated by resection within the bladder and bladder instillment with bacillus Calmette-Guérin or chemotherapy. For bacillus Calmette-Guérin-refractory disease, systemic anti-PD-1 (programmed cell death protein 1) immune checkpoint inhibition is a treatment. Our aim is to test whether intravesical instillment with anti-PD-1 inhibitor treats localized bladder cancer as effectively as systemic administration.